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P. M. Henson, and G. S. Worthen
Departments ofMedicine and Pediatrics, National Jewish Centerfor Immunology and Respiratory Medicine; Departments ofMedicine,
Pediatrics, Pathology, and Dermatology, University ofColorado School ofMedicine; and
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Abstract
The neutrophil has been implicated as an important mediator of
vascular injury, especially after endotoxemia. This study ex-
amines neutrophil-mediated injury to human microvascular en-
dothelial cells in vitro. We found that neutrophils stimulated by
formyl-methionyl-leucyl-phenylalanine (FMLP), the comple-
ment fragment C5a, or lipopolysaccharide (LPS) (1-1,000 ng/
ml) alone produced minimal endothelial injury over a 4-h assay.
In contrast, neutrophils incubated with endothelial cells in the
presence of low concentrations of LPS (1-10 ng/ml) could then
be stimulated by FMLP or C5a to produce marked endothelial
injury. Injury was maximal at concentrations of 100 ng/ml LPS
and 1o-7 M FMLP. Pretreatment of neutrophils with LPS re-
sulted in a similar degree of injury, suggesting that LPS effects
were largely on the neutrophil. Endothelial cell injury produced
by LPS-exposed, FMLP-stimulated neutrophils had a time
course similar to that induced by the addition of purified human
neutrophil elastase, and different from that induced by hydrogen
peroxide (H202). Further, neutrophil-mediated injury was not
inhibited by scavengers of a variety of oxygen radical species,
and occurred with neutrophils from a patient with chronic gran-
ulomatous disease, which produced no H202. In contrast, the
specific serine elastase inhibitor methoxy-succinyl-alanyl-alanyl-
prolyl-valyl-chloromethyl ketone inhibited 63% of the neutrophil-
mediated injury and 64% of the neutrophil elastase-induced in-
jury. However, neutrophil-mediated injury was not inhibited sig-
nificantly by 50% serum, 50% plasma, or purified a, proteinase
inhibitor. These results suggest that, in this system, chemotactic
factor-stimulated human neutrophil injury of microvascular en-
dothelial cells is enhanced by small amounts of LPS and may
be mediated in large part by the action of neutrophil elastase.
Introduction
Bacterial endotoxins have been implicated in the pathogenesis
of a wide variety of human and animal disorders (1). In partic-
ular, endotoxemia appears to result in injury to a number of
crucial organ systems, especially lung and kidney. With regard
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to the lung, the adult respiratory distress syndrome (ARDS)'
may occur in conjunction with endotoxemia, and is associated
with severe injury to the gas-exchange apparatus (2). In human
beings, where neutrophils can be recovered from broncho-al-
veolar lavage in early stages (3), and in animals, where infusion
of endotoxin produces lung injury (4) that is abolished by neu-
trophil depletion (5), the neutrophil has been suggested to play
a central role in the pathogenesis of endotoxin-associated lung
injury (6). The neutrophil has also been implicated in the patho-
genesis ofthe generalized Schwartzman reaction, in which renal
cortical necrosis and severe vascular injury have been shown
after two sequential endotoxin injections. This type of vascular
injury response was also abolished by prior depletion of circu-
lating neutrophils (7).
The mechanisms by which endotoxin promotes neutrophil-
mediated vascular injury are unclear, since endotoxin has many
actions (8). Early interest centered on the ability of the lipo-
polysaccharide (LPS) fraction ofendotoxin (which possesses most
of the biologic activity) (9) to activate complement intravascu-
larly (10). However, although intravascular generation ofpotent
complement-derived chemotactic factors may be important, a
considerable body of data suggests that complement activation
by itself is insufficient to produce severe lung or kidney injury
(11, 12).
In this regard, we have recently shown that even small
amounts of LPS may serve to enhance both the stimulation of
neutrophils in vitro and neutrophil-mediated injury in vivo.
Thus, in vitro, LPS at concentrations of 1-10 ng/ml "primes"
neutrophils such that they respond to chemotactic factors with
an enhanced release of toxic oxygen radicals (13) and lysosomal
enzymes (14). LPS has also been shown directly to stimulate
neutrophil adherence to plastic (15), and in our studies, to human
endothelial cells.2 In vivo, we have found that the simultaneous
infusion of both chemotactic factors and trace amounts of LPS
(100 ng) in rabbits enhanced neutrophil sequestration within
the lung, at least partly reflecting neutrophil adherence. In ad-
dition, the infusion of chemotactic factors and LPS led to a
marked enhancement ofneutrophil-mediated injury to lung en-
dothelium, which was associated with increased vascular per-
meability (submitted for publication).
1. Abbreviations used in this paper: AAPVCK, methoxy-succinyl-alanyl-
alanyl-prolyl-valyl-chloromethyl ketone; ARDS, adult respiratory distress
syndrome; C5a, chemotactic fragment of the fifth component of com-
plement; DMSO, dimethyl sulfoxide; FMLP, formyl-methionyl-leucyl-
phenylalanine; "1 'In, "'indium-tropolonate; LDH, lactate dehydrogenase;
LPS, lipopolysaccharide; a, PI, a, proteinase inhibitor; PMA, phorbyl
myristate acetate; SOD, superoxide dismutase; TLCK, N-alpha-tosyl-L-
lysine-chloromethyl ketone.
2. Unpublished observations that show LPS increases neutrophil adher-
ence in a dose-dependent manner to human endothelial cells.
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Just as the mechanisms by which LPS exerts its effects are
unclear, so are the mechanisms by which neutrophils injure tis-
sues. Both oxygen radicals (16-18) and neutrophil-derived pro-
teases (19, 20) have been implicated in neutrophil-mediated in-
jury to the endothelium in vivo, in isolated perfused organs, and
to cultured endothelial cells in vitro.
Accordingly, the goals of this study were twofold. First, we
sought to examine the interaction ofLPS with stimulated human
neutrophils and cultured human microvascular endothelial cells,
to test the hypothesis that LPS would enhance neutrophil-me-
diated injury stimulated by chemotactic factors. Second, these
experiments permitted us to begin to investigate the mechanisms
by which neutrophils injure human endothelial cells.
We show that LPS in low concentrations (1-10 ng/ml) was
capable of enhancing stimulated neutrophil-mediated injury to
endothelial cells. Further, we demonstrate that neutrophil elas-
tase was the major identifiable injurious agent. These data may
be relevant to LPS-induced vascular injury in vivo.
Methods
Reagents. All reagents and plasticware used in this assay were tested
before use for the presence ofLPS using the Limulus Amebocyte Lysate
kit from Associates ofCape Cod, Inc. (Woods Hole, MA). This procedure
detects as little as 0.01 ng LPS/ml. Sterile plastics were free of detectable
LPS contamination, and all reagents, tested at the concentration used
in the injury assay, contained <0.1 ng/ml LPS with the exception of
human neutrophil elastase, which had 1 ng LPS/0. 1 U of elastase.
The assay buffer employed was Kreb's-Ringer phosphate buffer, pH
7.2, with 0.2% dextrose (5% dextrose in 0.2% sodium chloride, injectable,
Abbott Laboratories, North Chicago, IL) and 0.5% human serum albumin
(prepared without preservatives or detectable LPS levels in a 1% solution
by Cutter Laboratories, Emeryville, CA). The salts comprising the buffer
were purchased from Mallinkrodt (Paris, KY), and had undetectable
LPS levels. All components were freshly diluted with LPS-free saline
(0.9% saline for irrigation, Abbott Laboratories) on each experimen-
tal day.
LPS was prepared by the method of McIntire (21) from Escherichia
coli K235 and was a kind gift ofDr. David Morrison ofEmory University,
Atlanta, GA. The lyophilized LPS was dissolved in LPS-free saline at
500 ug/ml. Frozen aliquots were thawed and sonicated using a Sonicator
Cell Disrupter (Ultrasonics, Inc., Plainview, NY) with a microtip at an
amplitude setting of 2 for two 10-s periods before being diluted in assay
buffer.
The biologically active chemotactic fragment ofthe fifth component
of complement (C5a) was purified from human serum by a procedure
modified from that of Fernandez and Hugh (22), as reported previously
(23). The chemotactic factor formyl-methionyl-leucyl-phenylalanine
(FMLP, Vega Biochemicals, Tucson, AZ) was kept frozen in dimethyl
sulfoxide (DMSO, Fisher Scientific Co., Fair Lawn, NJ) at l0-3 M and
diluted in assay buffer.
Human neutrophil elastase was purified according to the method of
Baugh and Travis (24). The procedure involved affinity chromatography
of crude extracts of normal human neutrophil leukocyte granules using
bovine lung trypsin inhibitor (Sigma Chemical Co., St. Louis, MO) bound
to sepharose 4B (Pharmacia Fine Chemicals, Upsalla, Sweden). I U of
elastase was defined as the amount of elastase that solubilized 1 Mg of
insoluble bovine ligamentum nuchae elastin in 1 h at 37°C.
The specific elastase inhibitor methoxy-succinyl-alanyl-alanyl-prolyl-
valyl-chloromethyl ketone (AAPVCK) was custom synthesized by
Bachem, Inc. (Torrance, CA) (25). A trypsin and papain inhibitor, N-
alpha-tosyl-L-lysine-chloromethyl ketone (TLCK), was purchased from
Vega Biochemicals. Both the AAPVCK and TLCK were dissolved in
DMSO, then diluted to l0-4 M in assay buffer (0.05% DMSO, final
concentration). Human a1l proteinase inhibitor (a, PI) was purchased
from Sigma Chemical Co. and purified by affinity chromatography on
Cibacron Blue FG3-A (Pharmacia Fine Chemicals) to remove albumin
(26). After dialysis there was a single band on gel electrophoresis. Other
reagents added to the assay were superoxide dismutase (SOD, Diagnostic
Data, Inc., Mountain View, VA), catalase (17,600 U/mg, Sigma Chemical
Co.), sodium azide (Sigma Chemical Co.), thiourea (Sigma Chemical
Co.), and hydrogen peroxide (H202, Fisher Scientific Co.). Activity of
H202 was determined by its capacity to oxidize scopoletin (27).
Endothelial cells. Human microvascular endothelial cells were isolated
from fresh, healthy adipose tissue as described by Kern et al. (28). Briefly,
the tissue was minced, collagenase digested, and the suspension was sieved
through nylon mesh and layered onto a 5% albumin gradient. This pro-
cedure separated large endothelial clumps from fibroblasts and adipocytes
that were usually present as single cells. The yield was essentially pure
endothelial cells, which were plated into 35-mm diameter wells (Costar,
Cambridge, MA). The growth medium was MCDB 131, which contains
10 ng/ml epidermal growth factor (Sigma Chemical Co.), I gg/ml hy-
drocortisone (Sigma Chemical Co.), and 2% fetal bovine serum (Irvine
Scientific, Santa Anna, CA), and is a selective medium for endothelial
cells (29). The monolayers demonstrated the typical cobblestone mor-
phology of endothelial cells. In addition, the cells expressed Factor VIII
antigen and angiotensin converting enzyme activity and demonstrated
uptake of acetylated low density lipoprotein (28).
Human umbilical vein endothelial cells were harvested by collagenase
digestion according to the method ofGimbrone et al. (30) and grown as
previously described (31).
Neutrophils. Human blood neutrophils were prepared using plasma-
Percoll gradients and avoiding LPS exposure, by a method we have pre-
viously described (14). In brief, whole citrated blood was centrifuged,
the packed cells sedimented through 6% dextran, and the mixed leu-
kocytes then separated through 42 and 51% plasma-Percoll gradients.
The resulting neutrophil preparation was 95% pure and 99% viable based
on trypan blue exclusion. Neutrophils isolated by this procedure showed
enhanced chemotactic responsiveness, less spontaneous change of shape,
and lower baseline secretion ofsuperoxide anion and lysosomal enzymes
than did neutrophils prepared by the traditional Ficoll-Hypaque method
(14). The effects of Ficoll-Hypaque preparation on neutrophil behavior
in vitro could be duplicated in the plasma-Percoll cells by the addition
of small amounts of LPS (14).
Injury assay. The assay used was a modification of previously de-
scribed monolayer injury assays (18, 20). The primary cultures of en-
dothelial cells were passed by trypsinization into 1-cm2 assay wells (Costar)
and maintained 2-3 d postconfluence (1-2 X lIO cells/well). On the day
of assay, the endothelial cells were washed twice with assay buffer. To
label the monolayers, "'indium-tropolonate ("'In) (72 mCi/ml, New
England Nuclear, Boston, MA) at 10 MCi/ml was first incubated with 4
X 10- M tropolone (Sigma Chemical Co.) in assay buffer for 1 min,
and this solution was then added to the cells to achieve a final concen-
tration of 4 X l0-4 M tropolone and 1 MCi of "'In per I01 cells. The
monolayers were incubated for 15 min at 25°C, washed three times with
assay buffer, and used immediately. The cells incorporated 10% ofthe
added label to give an average of 177,000 cpm/I05 cells.
Neutrophils, suspended in assay buffer, were added to the endothelial
monolayers at a final concentration of 1 X 106/well (10 neutrophils to
1 endothelial cell). LPS with or without other inhibitors were added at
this time to triplicate sample wells. In other wells, neutrophil elastase or
H202 was added in the absence of neutrophils. The assay was incubated
for 1 h at 37°C in a humidified, 5% CO2 incubator. The chemotactic
factors FMLP or C5a were then added to the appropriate wells, and the
incubation was continued for an additional 3 h. To determine sponta-
neous release for each experiment, triplicate control wells containing 1.1
ml (the final fluid volume of all the reaction mixtures) of assay buffer
were incubated in parallel for the 4-h period. At each hour, 100 Ml was
carefully removed from all wells and placed in tubes to be counted in a
Beckman 8000 gamma counter. After 4 h of incubation, the wells were
gently washed three times with assay buffer. The wash fluids from each
well were pooled, centrifuged at 250 g for 6 min, and the supernatant
and pellet were separated for counting. Cumulative "'In release over
time was calculated by correcting each hourly aliquot for the total well
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volume at that time. In contrast, total cpm released was determined by
adding the cpm in each aliquot to that in the washes at the end of the
experiment that might include loosely adherent radioactivity released by
the washes. Releasable cpm for each experiment were determined by
subjecting triplicate monolayers to two freeze-thaw cycles and washing
as described above (an average of 71.9±4.7% [SEM] of the incorporated
radioactivity was released). If A(rm) = cpm in each 100-ul sample from
hours 1-4, B = cpm in supernatant from washes, C = cpm in pellet
from washes, and T = cpm releasable by freeze-thaw, then percent I'IIn
release at each time point was calculated as: (A X well volume correction)/
(T) X 100, and the total percent "'In release was calculated as: (A(,l4) +
B + C)/(T) X 100. Results displaying total percent "'In release include
the percentage of counts present in the pellet from each well washing as
calculated by (C)/(T) X 100. Percent inhibition was determined by the
formula: 1 - (% release with inhibitor - spontaneous release)/(% release
without inhibitor - spontaneous release) X 100.
In three experiments, we compared the release of "I'In to the release
of the cytoplasmic enzyme lactate dehydrogenase (LDH) (32) from en-
dothelial monolayers. Monolayers were subjected to 1, 2, or 3 freeze-
thaw cycles, the wells were washed, and LDH or "'In was measured
from the supernatant only. "'In and LDH release correlated well (cor-
relation coefficient of 0.84).
Release of °2 by neutrophils. Release of O2 from neutrophils was
determined as described by Johnston et al. (33) using SOD-inhibitable
reduction of cytochrome c. Neutrophils (2.5 X 106) were preincubated
for I h at 370C in suspension with assay buffer or 1 gg/ml LPS (plus,
when appropriate, SOD or AAPVCK). The stimulus FMLP was then
added along with cytochrome c, and the reaction mixture was incubated
for 10 min at 370C.
Electron microscopy. Pellet material from several wells ofendothelial
cells that had been incubated with LPS/FMLP-stimulated neutrophils
was collected, fixed in 1.5% glutaraldehyde in 0.1 M cacodylate buffer,
postfixed in osmium, and dehydrated in ethanol. Thin sections were
poststained with uranyl acetate and Reynold's lead and viewed on a
Philips 400 T electron microscope.
Statistics. The effect of differing treatments on total "'In release
from endothelial cell monolayers was compared by one-way analysis of
variance and the Tukey multiple comparisons test, calculated using a
proprietary statistical package (Statistical Analysis System, Gary, NC).
Comparisons between the time course of release under various conditions
were made employing a Bonferroni multiple comparison test analyzing
the log of the differences between different groups. This latter analysis
was performed on another proprietary statistical package (BMDP, Inc.,
Los Angeles, CA). Groups were considered different if the P value was
<0.05.
Results
Effect ofLPS on neutrophil-mediated endothelial injury. The
protocol of these experiments was based on the previously dis-
cussed ability of LPS to increase neutrophil adhesiveness and
to prime neutrophils for an enhanced response to chemotactic
factor stimulation. Endothelial cells and neutrophils were in-
cubated together with LPS for 1 h before the addition of the
chemotactic factors to stimulate neutrophil secretion ofenzymes
and oxygen metabolites.
As shown in Fig. 1, the incubation of LPS with neutrophils
and endothelial cells and subsequent addition of a high dose of
the stimulus FMLP (10-6 M) caused substantial endothelial in-
jury after 4 h, as assessed by "'In release. Neutrophils stimulated
with the same concentration of either FMLP or LPS alone did
not elicit significant release of " 'In from endothelial monolayers.
LPS and FMLP in the absence of neutrophils had no injurious
effect, thus indicating that neutrophils played a necessary role.
The percent of label present in the pellet (obtained by cen-
Buffer
n-18
Neutrophils
I
Neutrophils+LPS
n- 7
Neutrophils+FMLP
n-l 1
LPS+FMLP
n-6
ni- B
Total %...In Release
10 20 30 40
Wz-zzz-I
pellet-.nZ -supernatant
WA--
Figure 1. The effect of LPS and FMLP on neutrophil-mediated endo-
thelial cell injury. Neutrophils in the presence or absence of 1 /Ag/ml
LPS were incubated for I h with endothelial cells (10 neutrophils to 1
endothelial cell) before the addition of 10-6 M FMLP to the appropri-
ate wells. After an additional 3 h of incubation, the wells were washed
and the washes separated into pellet and supernatant and counted.
Control wells containing buffer were incubated in parallel for 4 h.
Data is depicted as the mean±SEM of the number of experiments in-
dicated. The shaded area represents the mean± I SEM of the control
release. Neutrophils + LPS + FMLP caused significant injury (P
= 0.003) (*)-
trifugation ofthe wash buffers at the end ofthe incubation) from
each test condition is also depicted in Fig. 1. It should be noted
that pellet counts were extremely low, indicating minimal de-
tachment of intact endothelial cells. "'In cpm in the pellet from
buffer control wells was 2.1±0.4% of the total releasable cpm,
whereas in wells containing neutrophils plus LPS and FMLP it
comprised 4.7±0.7%. Pelletable counts thus remained a small
and relatively constant percentage of the radioactivity released
into the medium by the various treatments, ranging from 16.4
to 18.6% of the cpm actually released in all samples.
The pellet from wells incubated with neutrophils, LPS, and
FMLP was examined by both light and electron microscopy.
After the low-speed centrifugation described in the assay pro-
tocol, the pellet contained many neutrophils, considerable debris,
and very few whole endothelial cells. Using trypan blue exclusion
as a measure of viability, the neutrophils were able to exclude
trypan blue while 90% of the endothelial cells took up trypan
blue. Electron microscopy revealed neutrophils and disrupted
endothelial cells in the pellet, as shown in Fig. 2. Taken together,
these data suggest that, in this system, "'In release was a con-
sequence of endothelial cell lysis rather than detachment.
During endotoxemia, and thus after interaction with blood
components, concentrations of circulating LPS have been mea-
sured to be between 0.5 and 5 ng/ml (34), figures that likely
represent an underestimate of the amount of LPS available for
transfer to membranes. We therefore investigated the concen-
tration ofLPS necessary to promote neutrophil-mediated injury
using 10-6 M FMLP as the stimulus. As shown in Fig. 3, an
effect on "'In release was seen at LPS concentrations as low as
1-10 ng/ml, and the injury reached a maximum at concentra-
tions of 100-1,000 ng/ml. In most subsequent studies, in order
to enhance the signal-to-noise ratio, we employed a maximal
LPS concentration of I usg/ml.
The effect of different concentrations of FMLP was also
studied and results are shown in Fig. 4. Measurable injury was
Neutrophil-mediated Endothelial Injury 1235
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Figure 2. Transmission electron micrograph of the pelletable material
from injured endothelial monolayers. The endothelial cells were incu-
bated with 106 neutrophils and 1 ug/ml LPS for 1 h, 10-6 M FMLP
was added, and the incubation continued for a total of 4 h. The wells
seen at 10-8 M and a maximum effect was achieved at concen-
trations of 10-7 M or higher. The biologically relevant comple-
ment component C5a was tested for its capacity to stimulate
neutrophil-mediated injury. Incubation of neutrophils with l0-7
M C5a and 1 ltg/ml LPS resulted in the same magnitude of
endothelial injury as that seen using l0-7 M FMLP and LPS
("'In release was 28.7±4.7% with neutrophils incubated with
C5a and LPS, compared with 13.0±1.2% for neutrophils and
C5a alone, n = 4).
Pretreatment studies. LPS has been shown to affect both
neutrophils (I3-15)2 and some types of endothelial cells (20).
In an attempt to determine whether the effect of LPS was to
increase the injurious potential of the neutrophil, or to increase
the susceptibility of the endothelial cell, neutrophils and endo-
thelial cells were separately pretreated with LPS before assaying
injury. The results are shown in Fig. 5. Neutrophils were exposed
to 100 ng/ml LPS for 1 h, washed, and then added to the en-
dothelial cells with FMLP. This procedure produced nearly the
same magnitude of injury seen with co-incubation of neutrophils
and LPS with endothelial cells. In contrast, pretreatment of en-
dothelial cells with LPS (up to 1 ,ug/ml) for 1 h before washing
and the addition ofneutrophils and FMLP resulted in little "'In
were washed and the pellets from these washings were fixed and pro-
cessed as described. An apparently intact neutrophil is shown sur-
rounded by endothelial cell debris. X 9,200.
release above baseline. It is not known how much LPS adhered
to the surface of the endothelial cells and the culture well after
washing. It is possible, therefore, that some residual LPS was
available to act on the neutrophils. Conversely, LPS itself may
have had a small direct effect on the endothelial cells. Neutrophils
pretreated with LPS and then added to the endothelial cells with
buffer alone also produced a small increase in "'In release. Under
these circumstances, the centrifugation of the neutrophils after
LPS priming may have caused some activation. In agreement
with our other data, endothelial cells pretreated with LPS before
the addition of neutrophils, without stimulus, released no more
"'In than buffer controls. From these data, it appears that, in
this system, LPS acts primarily on the neutrophil to enhance
neutrophil-mediated injury.
Time course of injury: effects of neutrophils, elastase, and
H202. Injury to endothelial cells was followed over the 4-h assay
and the results are shown in Fig. 6. "'In release is depicted as
the cumulative value at each time point by counting an aliquot
and correcting for the well volume. Although there was some
label present in the supernatant at the start of the incubation,
as shown by the release obtained in the presence ofbuffer alone,
the endothelial cells released almost no additional label spon-
1236 Smedly et al.
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Figure 4. Injury response to varying concentrations of FMLP. Endo-
thelial cells and neutrophils were incubated with 1 Ug/ml LPS for 1 h
before the addition of FMLP. After an additional 3 h of incubation
it I the wells were washed and the total % "'In release was calculated.
0.1 1.0 Points represent the means and the bars the SD of three determina-
tions.
Figure 3. The effect of varying concentrations of LPS on release of
I"'In from cultured endothelial cells. Neutrophils and endothelial cells
were incubated with each concentration of LPS for 1 h before the ad-
dition of 10-6 M FMLP. After a total of 4 h of incubation, the wells
were washed and the total percent "'In release was calculated. The
points represent the means and the bars the SD of triplicate wells in
two experiments.
thelial cells was 30.9±3.4%, with 4.8±2.0% present in the pellet
(three experiments). Thus, this concentration ofneutrophil elas-
tase caused endothelial cell lysis of the same time course and
magnitude as that produced by LPS/FMLP-stimulated neutro-
% Buffer Control
taneously during the next 3 h ofincubation. Spontaneous release
of "'In was calculated to be 0.05%/h during the 0-3-h incubation
period. When neutrophils were incubated with endothelial cells
and LPS and then stimulated with FMLP, there was significant
(P = 0.003) injury within 1 h after the addition of FMLP, and
the magnitude of this injury increased substantially over the
next 2 h. The rate of release of label was calculated to be
3.5%/h, greatly enhanced when compared with release from
buffer-containing wells.
To compare neutrophil-mediated injury with injury caused
by defined mediators that might be produced by stimulated neu-
trophils, H202 and purified neutrophil elastase were added to
endothelial monolayers as agents that might cause oxidant and
proteolytic injury, respectively. The reagents were added at time
zero and incubated for 4 h following the same protocol as for
the neutrophil injury system. Purified human neutrophil elastase
at 0.5 U/ml (an amount calculated to equal - 10% of the total
neutrophil elastase present in 106 neutrophils) (35) was able to
elicit lytic injury with a time course similar to that ofneutrophil-
mediated injury (Fig. 6). Including the washes at the end of the
experiment, the total "'In release from elastase-treated endo-
Pretreat --Add to ECI 20 40 60 80 100 120 140
N+LPS
EC+LPS
N+LPS
EC+LPS
N+LPS+FMLP
FMLP
N+FMLP
Buffer
N.Buffer
160 180 200
H--
I
II
Figure 5. The effect of pretreatment of neutrophils or endothelial cells
with LPS. Endothelial cells were incubated with LPS at 100 ng/ml for
1 h at 37°C, the monolayers were washed twice, and neutrophils were
added with buffer or 1O-6 M FMLP. Neutrophils were pretreated with
100 ng/ml LPS for 30 min at 37°C, washed once, and incubated at
room temperature for a total pretreatment time of 1 h. With either
pretreatment, neutrophils and endothelial cells were mixed with buffer
or 10-6 FMLP and the wells were incubated an additional 3 h. Data
are depicted as the mean±SEM of three experiments. Pretreatment of
neutrophils with LPS before adding FMLP caused significantly greater
injury than pretreatment of endothelial cells.(*) (P = 0.02).
Mean±SEM "'In release for buffer controls was 11.3±7.4%.
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Figure 6. The time course of "'In release from endothelial mon
injured by stimulated neutrophils, H202, or elastase. At -1 h, n
phils and 1 ug/ml LPS were added to endothelial monolayers. A
time, 10-6 M FMLP was added to the appropriate wells and the
bation was continued for a total of 4 h. Elastase (0.5 U/ml) or I-
(10-4 M) was added to endothelial cells and incubated for 4 h. A
hour, 100 IAl was removed from each well and counted and the
lative "'In release was calculated. The points represent the meai
the bars the SEM; the number of experiments is indicated in pa]
ses. Compared with FMLP-stimulated neutrophil controls, neut
+ LPS + FMLP caused significant release at 1 h(*) (P = 0.003),
the magnitude of the injury increased over the second and third
(P = 0.0001).
phils without inducing detachment of cells (i.e., increasing
in the pellet). Higher concentrations of elastase caused"
lease earlier, and endothelial cells exposed to 4 U/ml el
were observed to have become "round" but not detached
end of the incubation period.
Hydrogen peroxide at lo-4M elicited comparable tota
release to that produced by neutrophils sequentially stim
with LPS and FMLP. This concentration of H202 is ap
mately fivefold greater than that measured in vitro after
ulation of neutrophils with LPS and FMLP (13), but was se
on the assumption that local levels of H202 at the cell s
would be considerably higher than amounts in the superr
As can be seen by reference to the time course in Fig. 6, alt
H202 produced a similar amount of label release from t
dothelial cells, the time course differed from that of neuti
mediated damage. In contrast to stimulated neutrophils
tase, H202 did not cause significant label release into the al
until the fourth h ofincubation. However, the total label'
at the end of the fourth hour, which includes washes that
release loosely adherent counts, was 58.9±10.9%, with 8.3
present in the pellet.
Human umbilical vein endothelial cells, which havy
commonly used in endothelial injury systems, were also em-
ployed for these studies. In experiments comparing microvas-
(18) cular with umbilical vein endothelial cells, the time course and
magnitude of neutrophil-mediated injury was similar for the
se (3) two cell types, although umbilical vein cells were able to be
i14) injured by neutrophils and FMLP alone (data not shown). The
two kinds ofendothelial cells responded quite differently to H202-
induced injury, however. Hydrogen peroxide at 1o-s M elicited
significant "'In release from umbilical vein cells (196.4±8.3%
of buffer controls over 4 h, n = 4), but this same concentration
caused minimal injury to microvascular endothelial cells
(119.5±11.8% of buffer "'in release over 4 h, n = 4). Thus,
umbilical vein endothelial cells may be more susceptible to ox-
idative injury than microvascular endothelial cells.
Mechanism of injury. Since the time course of neutrophil-
mediated injury paralleled that due to elastase, but was quite
different from that of injury induced by H202, we studied neu-
trophils from a patient with chronic granulomatous disease (36).
In one experiment, performed in quadruplicate, these neutro-
phils, which were shown not to produce superoxide anion or
H202, induced "'In release from endothelial cells that was
equivalent to that of normal neutrophils when both were in-
cubated with LPS and stimulated with FMLP (chronic granu-
lomatous disease neutrophils caused 144.4±21.2% "'In release
over buffer controls, compared with 144.7±19.7% "'In release
with normal neutrophils).
olayers Inhibitor studies were begun to assess the relative roles of
ieutro- proteinases and oxygen radicals in neutrophil-mediated endo-
Lt zero thelial injury. All of the inhibitors were added at the time ofthe
incu- addition of neutrophils and LPS, i.e., 1 h before the addition of
10each FMLP to the assay system. As seen in Fig. 7, endothelial injury
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Figure 7. The effect of inhibitors of oxidative or proteolytic activity on
endothelial injury. Neutrophils, 1 ug/ml LPS, and the inhibitors at the
concentrations shown were incubated with endothelial monolayers for
1 h before the addition of 10-6 M FMLP. After an additional 3 h in-
cubation, the wells were washed and the washes separated into pellet
and supernatant and counted. Data is depicted as the mean±SEM of
the number of experiments indicated. The shaded area represents the
mean±1 SEM of the spontaneous release. The stimulated neutrophil-
mediated injury was significant (P = 0.0001)(**), and the inhibition of
injury by the combination of AAPVCK + catalase + SOD was signifi-
cant at P = 0.05(*). No other inhibitors shown had a significant effect
on injury. Percent inhibition was calculated by averaging the mean
percent inhibition from each experiment.
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species (catalase and SOD), and the specific elastase inhibitor
AAPVCK. Catalase or SOD alone had no significant effect at
either the dose shown or at a dose 100 times (catalase) or two
times (SOD) more concentrated. Although they were ineffective
at inhibiting neutrophil-mediated injury, both of these agents
were tested in separate experiments and shown to be active
against H202 or O°, using specific assays for these radicals (33,
37). Catalase at 2.5 ,g/ml inhibited endothelial injury produced
by 10-4 M H202 by 95±4% (n = 4). SOD inhibited completely
the ferricytochrome c reduction that results from O- production
by stimulated neutrophils (100%, n = 6). The combination of
catalase and SOD also had no significant inhibitory effect on
endothelial injury over the 4 h of the assay (Fig. 7). Thus, the
combination of catalase and SOD did not reproduce the inhi-
bition produced by catalase + SOD + AAPVCK. Since catalase
and SOD are relatively large molecules, we considered it possible
that they might not be present in high enough concentration at
the neutrophil-endothelial interface. Accordingly, a smaller
molecule that scavanges hydroxyl radicals, thiourea (37), was
tested. Neither this agent nor azide, an inhibitor of myeloper-
oxidase (38), inhibited neutrophil-mediated injury (Fig. 7). In
data not shown, DMSO, which also scavanges hydroxyl radicals
(39), was unable to inhibit injury (% inhibition = 11%).
The effects of the specific elastase inhibitor AAPVCK and a
related inhibitor, TLCK, are demonstrated in Fig. 8. At a con-
centration of 10-5 M, AAPVCK was nearly as effective (63%
inhibition) as the combination of inhibitors (catalase + SOD
+ AAPVCK, 75% inhibition). Higher concentrations showed
no additional inhibitory activity (data not shown). The related
chloromethyl ketone derivative, TLCK, which inhibits trypsin
and papain but lacks specificity for elastase, was added at the
same concentration and caused slight, but statistically insignif-
icant, inhibition. The combination ofTLCK, catalase, and SOD
had no significant inhibitory effect, in marked contrast to the
combination of AAPVCK, catalase, and SOD. AAPVCK, but
not TLCK (both at 10-' M), was able to inhibit injury caused
by purified neutrophil elastase (0.5 U/ml) to approximately the
% hhibition
75
63
23
a
Buf f e
n-6
N+LPStFMLP
n-6
N+LPS+FMLP+
AAPVCK-catSOD
nl=5
N+LPSuFPM LP+
AAPVCK 1 3 'M
n=5
NhLPS+FNILP+
TLCK 10 'M
n=3
N+LPS+FMLP
cat+SOD+TLCK
n=3
Total % 'In Release
n 1Z1 20 30 40- w ,t w w
Ht_ S. _ )__r _ __ .__ - . _ . _ .. __ . . _ .... _ _ ... _ _ . . . q;) _._. . _ ... __ j
4 *-H. . * _ _ ,_ _ _. . _ _ _._,. . . , _ _ _ _,, ,
pellet-E
*' . -r-- -- ._1. .
_ _ __ _ 4 . __ __ . .... _ _ _ ... __ .... .| _ |_ . .__ _. _ . J ]-supernatant
Figure 8. The effect of chloromethyl ketone inhibitors on inhibition of
endothelial cell injury. The protocol was the same as that described for
Fig. 7. Data is depicted as the mean±SEM of the number of experi-
ments indicated. The shaded area represents the mean± 1 SEM of
spontaneous release. The injury caused by neutrophils + LPS
+ FMLP was significant at P = 0.001(**). Significant inhibition was
seen with the combination of AAPVCK + catalase + SOD (P
= 0.05X*) as well as AAPVCK alone (P = 0.05)(*). Neither TLCK
alone nor the combination ofTLCK + catalase + SOD inhibited in-
jury to a statistically significant degree. Percent inhibition was calcu-
lated by averaging the mean percent inhibition from each experiment.
same degree (64.2±22.4%, n = 6) as it inhibited stimulated neu-
trophil-induced injury. Similarly, AAPVCK was able to inhibit
injury in our single experiment with chronic granulomatous dis-
ease neutrophils to a similar degree (60%). AAPVCK (l0-5 M)
had no effect on LPS-primed, FMLP-stimulated neutrophil ox-
ygen radical secretion, as assessed by superoxide release (n = 6).
Similarly, we found that this concentration ofAAPVCK did not
inhibit neutrophil chemotaxis in vitro (manuscript in prepara-
tion). In addition, 10-' M AAPVCK did not prevent H202-me-
diated endothelial cell injury when added at the same time as
H202. These data, taken together, suggested that neutrophil
elastase was an important mediator of endothelial injury in this
system.
Since blood, which contains several inhibitors of elastase
action, continually bathes endothelial cells, serum, plasma, and
a, PI were also included in the assay to assess injury in the
presence of physiologically relevant inhibitors. Autologous
serum, made by adding calcium to platelet-rich, citrated plasma,
was added with neutrophils and LPS to constitute 50% of the
assay medium. Platelet-poor plasma was made from the same
preparation by centrifugation of platelet-rich plasma. As shown
in Table I, injury was not affected by the presence of serum, and
the injury may even be slightly increased in the presence of
plasma. The serine protease inhibitor a, PI, which inhibits tryp-
sin, elastase, and tissue enzymes (40), also did not inhibit injury
at concentrations similar to those measured in normal human
plasma (1.5 mg/ml) (41).
Discussion
In this study we have employed an assay that measures injury
to cultured human microvascular endothelial cells. This injury
appears to represent cell lysis, since large amounts ofa label that
binds tightly to endothelial cells were found in the supernatant,
and release of this label correlated well with release of the intra-
cellular enzyme LDH. In addition, the pellet obtained after cen-
trifugation of washes contained cell debris and not intact en-
dothelial cells. The results of these experiments show that LPS
greatly enhanced the endothelial injury caused by FMLP or CSa-
stimulated neutrophils. The effects of the two stimuli were not
merely additive, since neutrophils incubated with either LPS or
FMLP alone caused minimal injury even in high concentrations.
Table L. Effect ofSerum, Plasma,
and a, PI on Endothelial Cell Injury
% Buffer control
N + LPS
N + LPS + FMLP
Additions + FMLP + addition
50% Serum (n = 3) 168.1±18.1 170.1±17.7
50% plasma (n = 4) 165.9±13.1 232.4±48.4
1.5 mg/ml a, PI (n = 3) 168.3±8.5 186.9± 11.4
The protocol was the same as that described for Fig. 7. Data is de-
picted as the percentage of "'In release by buffer control and is the
mean±SEM of the number of experiments indicated. The percent
"'In release from endothelial cells by buffer controls for the serum ex-
periments was 11.0+2.2%, for plasma 16.1±7.2%, and for a, PI
9.5±2.3%.
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Instead, the sequential incubation ofLPS followed by FMLP or
C5a with neutrophils and endothelial cells appeared to evoke a
synergistic response. The enhancement provided by LPS was
evident at very low LPS concentrations (1-10 ng/ml) comparable
to those described in human endotoxemic states (34). Similarly,
neutrophil-mediated injury in the presence of LPS was evoked
with as little as 108 M FMLP.
Our data, particularly the pretreatment studies presented
here, imply that LPS enhanced injury through its effect on the
neutrophil and not the endothelial cell, since neutrophils pre-
treated with LPS elicit the same magnitude of injury as the co-
incubation of neutrophils, endothelial cells, and LPS. However,
we cannot completely rule out an effect of LPS directly on en-
dothelial cells. Brigham and Meyrick (42) have suggested that
granulocyte-mediated injury may not occur unless the endothe-
lial cells have already been subtly harmed or altered. Thus, LPS
may affect the endothelial cell so as to make it more susceptible
to injury. In our system, LPS alone had no measurable injurious
effect over a 4-h incubation (see Fig. 1) or, in unpublished studies,
over a 24-h incubation (data not shown). Recent evidence sug-
gests that, unlike bovine endothelial cells, human umbilical vein
endothelial cells are not susceptible to injury by incubation with
up to 100 ,g/ml of LPS for 24 h (43). Our data would suggest
that resistance to direct LPS toxicity is a feature of human mi-
crovascular cells as well. Although enhanced endothelial sus-
ceptibility in terms of a subtle alteration cannot be ruled out by
either the apparent resistance to LPS alone or the pretreatment
data, we suggest that, in this system, LPS acts on the neutrophil
to enhance endothelial injury.
A number of groups have reported that neutrophils stimu-
lated by a single agent are capable of injuring endothelial cells
(18, 20). One factor that may contribute to these apparently
discrepant results is that neutrophil isolation procedures have
varied in different studies. We have shown (14) that neutrophils,
prepared by a traditional method using Ficoll-Hypaque gradients,
appeared to have been "primed" when subsequently tested for
various in vitro functions, as compared with cells prepared by
using plasma-Percoll gradients. One possible cause was exposure
of neutrophils to trace concentrations of LPS, which were de-
tected in reagents used in the traditional isolation method. These
observations and the current investigation indicate that very dif-
ferent results may be obtained if the neutrophils have been
primed during the isolation procedure. In particular, it may help
explain why some workers have induced endothelial injury with
a single stimulus, such as FMLP, C5a, or phorbyl myristate ac-
etate (PMA). In addition, our studies here suggest that human
umbilical vein endothelial cells, used commonly in studies of
injury, were able to be injured by neutrophils stimulated only
with FMLP.
This study further suggests that neutrophil-derived elastase
is the primary agent of endothelial cell injury in this system.
This conclusion is based on several pieces of evidence. The spe-
cific elastase inhibitor, AAPVCK, inhibited 60-70% of the neu-
trophil-mediated injury, whereas scavengers of oxygen metab-
olites had no effect on the injury. Neutrophils from a patient
with chronic granulomatous disease produced injury similar to
that produced by normal control neutrophils, and this injury
was inhibitable by AAPVCK. Purified human neutrophil elastase
caused damage in a neutrophil-free assay with a time course
similar to that ofstimulated neutrophils, and quite different from
that of H202-induced injury. Further, AAPVCK inhibited elas-
tase-induced injury to the same degree as it inhibited neutrophil-
mediated injury.
Some investigators have reported that oxygen species, either
H202 or O°, were the causative agent of neutrophil-mediated
injury to endothelial cells. Sacks and colleagues (18), using neu-
trophils stimulated with zymosan-activated plasma (18), and
Yamada and his co-workers (44), employing neutrophils incu-
bated with serum and large doses of LPS (44), have reported
that neutrophils injure endothelial cells by a catalase- and SOD-
inhibitable mechanism. Important differences in the assays may
have some bearing on this apparent discrepancy in results. One
factor is the type of endothelial cell chosen. Our assay employed
human microvascular endothelial cells for the major portion of
the work rather than the large vessel cells (either human umbilical
vein or bovine pulmonary artery) that have been used by other
investigators. In preliminary studies, reported here, umbilical
vein endothelial cells were 10 times more sensitive to H202-
induced injury than human microvascular endothelial cells. A
mechanism for this observation was provided by a recent study
that suggested that umbilical vein endothelial cells lack catalase
(45). It is plausible, therefore, that the type of endothelial cell
may, in part, determine the mechanisms by which they are in-
jured. Although adipose tissue, from which the microvascular
endothelial cells were isolated, is not commonly thought to be
injured during endotoxemia, the inflammatory responses in
which neutrophil-endothelial interactions are important occur
largely within microcirculatory beds. Accordingly, the study of
injury to microvascular endothelial cells may be particularly
relevant to the understanding of in vivo vascular injury.
In addition to the type ofendothelial cell studied, the stimulus
used to activate the neutrophils may have an effect on the en-
dothelial injury produced. Both Weiss et al. (46) and Martin
(47) demonstrated catalase-inhibitable endothelial injury using
PMA as a neutrophil stimulus. The time course of measurable
injury was markedly different from that of the neutrophil-me-
diated injury that was detectable within 1 h after FMLP stim-
ulation in our study. Weiss (46) reported measurable injury 3-
4 h after addition of stimulus, and Martin (47) did not see any
injury until after 8 h ofincubation. It is known that PMA, though
a good stimulator of oxygen metabolites, is a weak stimulus for
azurophil granule release (48). Clearly, oxygen metabolites such
as H202 can injure endothelial cells (see Fig. 6), and a massive
stimulus to their production would be expected to induce cellular
damage. Thus, injury stimulated by PMA may be more suscep-
tible to inhibition by serum and oxygen radical scavengers, than
that stimulated by FMLP or C5a as examined in this study.
Neutrophil proteases, particularly neutrophil elastase, have
been implicated in neutrophil-mediated endothelial injury by
Harlan and colleagues (20). In contrast to our results, however,
these investigators found endothelial cell detachment to be the
predominant response. Further, a recent study by these authors
suggested that neutrophils (isolated by the Ficoll-Hypaque
method) stimulated by FMLP may alter endothelial cells by ox-
ygen radical-independent mechanisms (49).
These data provide support for the concept that neutrophil-
mediated injury to endothelial cells may occur by many mech-
anisms, including both oxygen radical-dependent and -indepen-
dent ones. We have previously reported (13) that LPS prein-
cubation did not produce an increase in FMLP binding sites,
but did increase the V.. ofthe NADPH oxidase. More recently,
we have shown that LPS preincubation alters the neutrophil so
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as to enhance subsequently evoked neutrophil elastase release
(50). Similarly, LPS preincubation may increase neutrophil
elastase content (5 1). Thus, several ofthe major injury-inducing
substances of the neutrophil-oxygen metabolites and elastase
can be shown to be increased under conditions of LPS pretreat-
ment. Nonetheless, other neutrophil products, such as neutrophil
cationic proteins (see below) may be important. Further, the
potential interactions between the different neutrophil products
in terms of enhancing injury have not been well studied.
Even though, in our system, elastase can be implicated as
the major injurious agent from neutrophils, it is not clear how
elastase might produce endothelial injury. Bovine pulmonary
artery endothelial cells have been shown to produce elastin (52).
Although the elastin content of microvascular endothelial cells
is unknown, since elastase is active on a wide range ofsubstrates,
the degradation of other strategically located cell surface proteins
might produce injury. Elastase may also affect endothelial cells
via other mechanisms. For example, LeRoy et al. (53) have re-
cently suggested that the highly cationic nature of elastase may
alter endothelial cell function. This report is interesting in light
of the fact that in our studies, the specific elastase inhibitor
AAPVCK was not able to completely inhibit injury mediated
by either neutrophils or purified elastase. A potential compli-
cating factor is the contamination of our elastase preparation
by small amounts of LPS. Although we have been unable to
detect direct toxic effects of LPS on human microvascular en-
dothelial cells, we were concerned that the combination of LPS
and elastase might alter the effect of elastase. To address the
difference between elastase and H202, we have performed three
preliminary experiments in which pretreatment of endothelial
cells with LPS (10-1,000 ng/ml) for 1 h did not alter the sub-
sequent response to elastase or H202. These data (combined
with the pretreatment data reported herein) suggest that LPS
effects on the endothelial cell are of little importance over the
short time courses reported here, but do not address the potential
contribution of longer LPS incubations.
Although we identified enzymatically active neutrophil elas-
tase as the most important injury-causing constituent of the
neutrophil in this system, there may well be other neutrophil
products that are important in endothelial cell injury. In this
regard, it is of interest that neither serum or plasma, which con-
tain significant amounts of elastase inhibitor, nor relevant con-
centrations of purified al PI, inhibited neutrophil-mediated in-
jury. The reason for failure of the circulating antiproteases to
inhibit are unclear. Recent reports have suggested that aI PI can
be inactivated by neutrophil-derived oxygen metabolites (54,
55) or leukocyte-mediated proteinases (56). Thus, the neutrophil
itself might inactivate functional a1 PI. Additionally, close con-
tact between neutrophil and endothelial cell may be required
for injury. Inhibitors the size of al PI may thus not have access
to the interface where elastase action is critical (57).
Circulating endotoxin has been implicated in a variety of
syndromes of man and animals in which the primary manifes-
tation is vascular injury. These include ARDS (3) and both the
general (7) and local Schwartzman reactions. In the aforemen-
tioned settings, the neutrophil has been felt to play an important
role in the genesis ofvascular injury, based on both morphologic
criteria and depletion studies. However, as indicated, the mech-
anisms by which LPS promotes neutrophil-mediated vascular
injury, and the mechanisms by which neutrophils injure vascular
endothelium, remain unclear.
Recent work has focused on the ability of intravascular LPS
to activate complement systemically. Several lines of evidence,
however, suggest that complement activation alone may be in-
sufficient to produce lung injury in either humans or animals.
Animal studies from our laboratory (1 1) (submitted for publi-
cation) have shown that intravascular complement activation
or infusion of purified fragments ofC5 in rabbits fail to produce
functional or morphologic evidence of lung injury, although
neutrophils are effectively sequestered within the lung vascula-
ture. It should be pointed out, however, that studies in rats have
shown evidence of lung injury after intravascular complement
activation (16). Studies in humans further suggest that the gen-
eration of C5a is, by itself, insufficient to produce ARDS (58).
Similarly, systemic activation of complement in patients with
nephritis due to nephritic factor (59) has not been shown to lead
to lung injury. Taken together, these data imply the involvement
of multiple factors, including the generation of complement-
derived chemotactic factors, in the pathogenesis of ARDS.
In this setting, the ability of LPS to alter directly the behavior
ofneutrophils may be ofconsiderable importance. We have pre-
sented data from rabbits suggesting that the intravascular infusion
of LPS and complement-derived chemotactic factors produces
neutrophil-dependent lung vascular permeability and endothelial
injury (submitted for publication). In the present study, we sug-
gest that only when neutrophils are incubated with endothelial
cells in the presence of LPS can they be stimulated by chemo-
tactic factors such as FMLP or C5a to injure endothelial cells.
Further, this injury still occurred in the presence of 50% serum
or plasma and a physiologically relevant concentration of a1 PI,
the most potent circulating elastase inhibitor. Accordingly, we
suggest that LPS and chemotactic factors (or other neutrophil
stimuli) may act together to produce neutrophil-mediated vas-
cular injury, both in vivo and in vitro, and that this synergistic
interaction may help explain the pathogenesis ofvascular injury
in endotoxemia in both man and animals.
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